Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pemivibart
- Development stage
- Phase 3
- Lead developer
- Invivyd
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Pemivibart is a long-acting, human monoclonal antibody (IgG1λ) developed for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals aged 12 years and older who weigh at least 40 kg. It is administered intravenously and works by binding to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, thereby inhibiting its attachment to the human Angiotensin-converting enzyme 2 (ACE2) receptor and preventing viral entry into cells. Pemivibart has been engineered for an extended half-life and demonstrates neutralizing activity against multiple SARS-CoV-2 variants, including Omicron sublineages. It received emergency use authorization (EUA) from the FDA in March 2024 but is not fully approved[1][2][5][6].
- Brand names
- Pemgarda
- Other names
- adintrevimab-derived antibody
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on pemivibart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pemivibart.